Sign in

MIMETAS

@mimetas.bsky.social
48 followers 1 following 121 posts

We strive to contribute to groundbreaking therapies with our screenable, physiologically relevant 3D human disease models.

PostsRepliesMedia
MIMETAS @mimetas.bsky.social · 10/08/2026
🚀 MIMETAS has joined the @brukercorporation.bsky.social family! Through Bruker's majority investment in MIMETAS, we're combining advanced organ-on-a-chip models with multiomics, spatial biology, NMR and preclinical imaging. www.mimetas.com/news/bruker-...
041
MIMETAS @mimetas.bsky.social · 10/08/2026
🚀 MIMETAS has joined the Bruker family Through Bruker's majority investment in MIMETAS, we're combining advanced organ-on-a-chip models with multiomics, spatial biology, NMR and preclinical imaging. www.mimetas.com/news/bruker-...
000
MIMETAS @mimetas.bsky.social · 28/05/2026
🎉 Congrats to Dr. Gwenaëlle Rabussier on successfully defending her PhD dissertation at Maastricht University! Her thesis ‘Microfluidic placental barrier models of healthy and diseased pregnancies: for transport and toxicity studies’ is the result of the research she conducted at MIMETAS.
000
MIMETAS @mimetas.bsky.social · 27/05/2026
Introducing OrganoAccess™ A perfusable vascular bed for advanced 3D tissue modeling – 32 chips, zero pumps, 8+ weeks stable. Ready from day one for vascular tox & cardiovascular research. 🔗 mimetas.com/organoaccess #VascularBiology #OrganOnAChip
000
MIMETAS @mimetas.bsky.social · 18/05/2026
Kidney biology in 3D 🔬 Tubuloids + microfluidics = perfused, polarized tubules with functional transporters. A more human-relevant way to study renal function & drug interactions. 🔗 www.mimetas.com/kidney #KidneyResearch #OrgansOnChip
000
MIMETAS @mimetas.bsky.social · 13/05/2026
Ready-to-use Blood Vessel HUVEC model: Perfusable, membrane-free, human endothelial tubules with TEER readout. Built for vascular toxicity & inflammation studies—no setup needed. 🔗 shorturl.at/GAVVj #OrgansOnChip #DrugDiscovery
000
MIMETAS @mimetas.bsky.social · 12/05/2026
Immune-driven kidney injury is complex. Our immunocompetent proximal tubule-on-a-chip models inflammation, immune cell migration & drug response in one system. Explore the case study👇 shorturl.at/qji0D #KidneyResearch #OrgansOnChip
010
MIMETAS @mimetas.bsky.social · 07/05/2026
Platelets: protective or pro-inflammatory? Both. This vessel-on-a-chip study shows they: • ↑ permeability & immune cell migration • ↓ RBC leakage 🔗 Read the publication: shorturl.at/08LDq #OrgansOnChip #Immunology
010
MIMETAS @mimetas.bsky.social · 06/05/2026
How do you explain organ-on-a-chip to kids? You make it interactive 🎯 Great session by our scientists Jade and Marleen at Rijksmuseum Boerhaave – sparking curiosity in the next generation of scientists. #STEMeducation #OrgansOnChip
010
MIMETAS @mimetas.bsky.social · 30/04/2026
CAR T works in blood cancers, but solid tumors remain tough. Our tumor–vasculature-on-chip model lets you track T cell trafficking, infiltration & killing in 3D. Read our case study: shorturl.at/cgx31 #CARTcells #Immunotherapy
001
MIMETAS @mimetas.bsky.social · 29/04/2026
Great to host our Organ-on-a-Chip in Drug Discovery workshop in Tokyo Japan with Molecular Devices. Thanks to speakers from Taiho Pharma, Astellas Pharma & Univ. of Tokyo and all who joined for talks + live demos! Join a future workshop: www.mimetas.com/training #OrgansOnChip #DrugDiscovery
000
MIMETAS @mimetas.bsky.social · 23/04/2026
A patient-derived HCC-on-a-chip model to study tumor–vasculature interactions in liver cancer. Vascularized, high-throughput, and built for phenotypic + cytokine analysis. A step forward in modeling the tumor microenvironment in HCC. 🔗 shorturl.at/ufmE2 #HCC #LiverCancer #OrgansOnChip
000
MIMETAS @mimetas.bsky.social · 15/04/2026
Still relying on models that miss the tumor microenvironment? Our 3D tumor models capture what matters – vasculature, immune cells, and patient-derived tumors – for better oncology insights. 👉Explore our services: www.mimetas.com/oncology?utm...
000
MIMETAS @mimetas.bsky.social · 08/04/2026
A new publication from our customer, Labcorp! Their work highlights human vascular models that better predict immune-related risks - key as immunotherapies advance but bring challenges like cytokine release and vascular leak. 🔗https://shorturl.at/dxqAr
010
MIMETAS @mimetas.bsky.social · 30/03/2026
Predict GI toxicity earlier with an assay-ready, human-relevant colon model. The OrganoReady® Colon Organoid delivers multiplexed insights (TEER, viability, cytotoxicity, CYP3A4) in one workflow. 📄Download the app note: shorturl.at/L5rME
000
MIMETAS @mimetas.bsky.social · 26/03/2026
Live from Innovation for Health 2026 📍 Our CTO Bas Trietsch is on stage discussing how organ-on-a-chip is advancing human-relevant research and positioning the Netherlands globally. Great energy and discussions in the room! #InnovationForHealth #OrganonaChip #Biotech
000
MIMETAS @mimetas.bsky.social · 09/03/2026
How can we better model inflammation to improve immune-targeting therapies? In this webinar, learn how human-relevant 3D in vitro disease models help capture key inflammatory mechanisms and support better drug ranking and selection. 🎥Watch here: shorturl.at/UX8LY
000
MIMETAS @mimetas.bsky.social · 05/03/2026
Read our publication "Modeling hepatocellular carcinoma and its microenvironment on a chip" where we developed a vascularized, patient-derived HCC-on-a-chip model to study tumor–microenvironment interactions and screen 28 treatment conditions in HCC. doi.org/10.1038/s414...
doi.org
Modeling hepatocellular carcinoma and its microenvironment on a chip - Cell Death Discovery
Cell Death Discovery - Modeling hepatocellular carcinoma and its microenvironment on a chip
010
MIMETAS @mimetas.bsky.social · 02/03/2026
GI toxicity is a major hurdle in drug development. Our latest case study shows how the Perfused OrganoReady® Colon Organoid enables human-relevant GI safety assessment with real-time barrier, metabolic, and transport readouts. Read the full case study: www.mimetas.com/case-studies...
mimetas.com
Gastrointestinal Safety Asessment with the Perfused OrganoReady® Colon Organoid Model
Gastrointestinal toxicity is generally assessed in animal models but results in dogs and rats poorly predict negative results in humans. Traditional in vitro methods miss key physiological features li...
000
MIMETAS @mimetas.bsky.social · 24/02/2026
Learn how our Uniflow Technology delivers continuous unidirectional, physiological flow without external pumps, supporting robust vascular models for drug testing and immune–vascular studies. ⬇️ Download the poster: www.mimetas.com/resources/pe...
000
MIMETAS @mimetas.bsky.social · 18/02/2026
Behind the scenes 🎬 Last Thursday, the #NewDutch team visited MIMETAS to film. Our VP of Biology Henriëtte Lanz was interviewed, sharing how MIMETAS is advancing human-relevant research through our Organ-on-a-Chip technology. #Leidenstadvanontdekkingen #Leidencityofscience
000
MIMETAS @mimetas.bsky.social · 17/02/2026
New publication from MIMETAS 🧠 A scalable 3D human BBB model under gravity-driven, unidirectional flow. Built with self-assembling triculture microvasculature, it combines physiological relevance with higher-throughput capability for BBB research and drug discovery. 🔗 www.mimetas.com/news/mimetas...
021
MIMETAS @mimetas.bsky.social · 12/02/2026
Customer spotlight at #SLAS2026 Mayu Shibuta from Astellas Pharma showcased an Automated Organ-on-a-Chip Platform for Scalable Drug Testing using the OrganoPlate® platform! Automation + Organ-on-a-Chip = scalable, reproducible, human-relevant drug testing. #OrganOnAChip #Automation
000
MIMETAS @mimetas.bsky.social · 11/02/2026
Poster alert for #SLAS2026! Our collaborators at Tecan are presenting functional intestinal ADME/Tox testing using the MIMETAS OrganoReady® Colon Organoid Model + Tecan Spark Cyto. 📍Boston | Feb 11, 12–1 PM | Poster 1309-E www.mimetas.com/organoready-... #Organoids #ADMETox
000
MIMETAS @mimetas.bsky.social · 10/02/2026
We’re proud to share that MIMETAS is a founding member of IAMPS, the world’s first industry alliance dedicated to advancing microphysiological systems (MPS). With 8 other European innovators, IAMPS will accelerate regulatory acceptance, standardization & adoption of #NAMs. shorturl.at/dLRcF
010
MIMETAS @mimetas.bsky.social · 05/02/2026
Day 2 at #WORD+ 2026! Our team is ready to go at Booth #6 to discuss how MIMETAS' Organ-on-a-Chip models can not just support but accelerate your research projects. Also, don't forget to check out our poster on Predicting Gastrointestinal Toxicity!
000
MIMETAS @mimetas.bsky.social · 04/02/2026
Great start at #WORD+2026! Today, Pleun Hombrink (Director of Bioproduction & Screening at MIMETAS) shared how integrating colon organoids with MPS can enable more predictive, scalable drug discovery. Stop by booth #6 to meet the team! #NAMsInAction #Organoids #OrganOnAChip #MPS
000
MIMETAS @mimetas.bsky.social · 28/01/2026
We’re hiring a Junior Scientist at MIMETAS! 🧬 Join our Model Development team in Leiden and work hands-on with cutting-edge organ-on-a-chip technology to shape the future of drug discovery. 📍 Leiden, NL 👉 Apply here: mimetas.easycruit.com/vacancy/3585... #Hiring #LifeSciencesJobs #Biotech
020
MIMETAS @mimetas.bsky.social · 26/01/2026
Great discussions at Designing the Future Through Patient-Based Drug Development by Ombion. Our CEO Jos Joore presented on Enabling Human Biology in Regulatory Science, showing how fit-for-purpose #NAMs can strengthen regulatory decision-making and advance drug development.
010
MIMETAS @mimetas.bsky.social · 19/01/2026
💡 Publication spotlight: Swiss Institute of Allergy and Asthma Research researchers used the OrganoPlate® platform to develop Caco-2 and colon organoid models to study how food emulsifiers affect gut epithelial barrier integrity and inflammatory signaling. 🔗 onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
Mechanisms of gut epithelial barrier impairment caused by food emulsifiers polysorbate 20 and polysorbate 80
This study provides new insights into the underlying mechanisms of intestinal epithelial barrier defects in response to commonly used food emulsifiers P20 and P80. We demonstrated that P20 and P80 di...
120
MIMETAS @mimetas.bsky.social · 12/01/2026
🧠 Did you see the human BBB image we shared recently? In this webinar, learn how we develop a perfused human BBB model for disease modeling and DMPK studies, including stroke, neuroinflammation, toxicity testing, and drug transport: register.gotowebinar.com/register/189...
000
MIMETAS @mimetas.bsky.social · 09/01/2026
🧠 A fluorescence image of a human BBB model combining HBMECs, astrocytes, and pericytes. Claudin-5 (green), GFAP (red), and Hoechst (blue) reveal organized BBB architecture supporting studies of BBB function and drug transport. Discover the model: shorturl.at/APOzu
000
MIMETAS @mimetas.bsky.social · 06/01/2026
New drug modalities bring new safety challenges. Watch our on-demand webinar to learn how human 3D in vitro models & organ-on-a-chip improve toxicity prediction. shorturl.at/ONaf3 #DrugDiscovery #Toxicology #OrganOnAChip
000
MIMETAS @mimetas.bsky.social · 31/12/2025
Barrier dysfunction is key in gut disease and drug safety. Our study in MDPI Toxins shows a scalable, multi-parameter way to assess gut barrier integrity in MIMETAS' OrganoReady® gut models, supporting compound safety assessment and drug development. 🔗 www.mdpi.com/2072-6651/17...
000
MIMETAS @mimetas.bsky.social · 24/12/2025
Merry Christmas🎄✨ Thanks for being part of the MIMETAS journey in 2025 –good science, great collaborations, and yes… that website you may have already clicked through 😉 See you in the New Year!
000
MIMETAS @mimetas.bsky.social · 18/12/2025
The U.S. Senate has passed the FDA Modernization Act 3.0, moving FDA regulations closer to current nonclinical practice. The bill updates outdated “animal” testing language and supports broader use of human-relevant methods in drug development. buddycarter.house.gov/news/documen...
buddycarter.house.gov
Carter-led bill reducing unnecessary animal testing passes Senate
Rep. Buddy Carter, Serving Georgia's 1st District
000
MIMETAS @mimetas.bsky.social · 17/12/2025
Attivare Therapeutics (Wyss Institute spin-out) has joined Oncode Accelerator with a new Demonstrator Project, which MIMETAS is a key partner in. Together with Amsterdam UMC we’re working to improve translational oncology for hard-to-treat cancers. www.oncodeaccelerator.nl/news/wyss-in...
oncodeaccelerator.nl
Wyss Institute Spin-Out Attivare Therapeutics Joins Oncode Accelerator to Advance Novel Cancer Therapeutics | Oncode Accelerator
Accelerating the development of next-generation cancer therapies through collaboration and innovation. That is the mission of Oncode Accelerator. During the Oncode Accelerator Summit on December 4th, ...
000
MIMETAS @mimetas.bsky.social · 15/12/2025
✨ Last Friday, MIMETAS wrapped up the year with our Christmas Party! From dinner ➝ team-voted awards (Best Dressed, OrganoPlate Whisperer, PowerPoint Wizard, Energy Booster) ➝ dancing 💃🕺 We’re grateful for the people and energy that make MIMETAS what it is. #TeamCulture
000
MIMETAS @mimetas.bsky.social · 11/12/2025
Proud to be featured by the Netherlands platform! At MIMETAS, we’re working to transform drug development with human-relevant in vitro models that better predict clinical outcomes – accelerating safer, more effective medicines. 🔗 Read the article: nlplatform.com/articles/-MI...
nlplatform.com
Transforming pharmaceuticals with Organ-on-a-Chip technology
For every drug that reaches the market, pharmaceutical companies invest time and effort in dozens, if not hundreds, of drugs that ultimately fail. Dutch biotechnology company MIMETAS, led by CEOs Jos ...
000
MIMETAS @mimetas.bsky.social · 08/12/2025
Model choice matters in liver disease research. Our webinar shows how MIMETAS 3D in-vitro liver models are used for fibrosis, steatosis & metabolic assays, incl. automated anti-fibrotic screening. Watch: shorturl.at/mpQPc #LiverModel #Fibrosis #DrugDiscovery
000
MIMETAS @mimetas.bsky.social · 27/11/2025
This paper shows a microvascularized liver model with hepatocytes, stellate cells, and a self-organized perfusable endothelial plexus - native-like structure and HTS-ready robustness (excellent Z’). Big step for #MASH & anti-fibrotic screening research. Read here: shorturl.at/gOskI #LiverOnAChip
000
MIMETAS @mimetas.bsky.social · 25/11/2025
Looking for a physiologically relevant gut model in vitro? MIMETAS’ scalable 3D human gut models recreate key intestinal features, combining epithelium + perfused vasculature, stroma & immune components for more predictive barrier, ADME, toxicity & inflammation studies. shorturl.at/87E8x
000
MIMETAS @mimetas.bsky.social · 19/11/2025
❓How can we better model the human blood-brain barrier for CNS disease and drug development? From tight barrier formation to applications in stroke, neuroinflammation, toxicity testing, small-molecule transport, and antibody transcytosis - explore our 3D BBB-on-chip models: tinyurl.com/54wm4d4t
020
MIMETAS @mimetas.bsky.social · 18/11/2025
🚀 It’s here! We’re excited to unveil a fully redesigned website for MIMETAS. Built around how you explore science - from models and technology to screening, analysis, and ready-to-use tissues - all in one intuitive place. See for yourself: mimetas.com #OrganOnAChip #3DTissueModels #DrugDiscovery
000
MIMETAS @mimetas.bsky.social · 13/11/2025
🎓 Congrats to Dr. Murillo Bernardi on his successful PhD defense! His thesis, “From Chick to Chip - Novel models to bridge in vitro and in vivo kidney research” presents years of work on advancing predictive kidney models at UMC Utrecht and MIMETAS. #PhDDefense #MIMETAS
000
MIMETAS @mimetas.bsky.social · 11/11/2025
In this app note, learn how MIMETAS’ OrganoReady® Blood Vessel models enable high-throughput, human-relevant toxicity screening in 3D microfluidic blood vessel systems. Ultimately, this supports the development of safer therapeutics and better treatment strategies. 🔗 shorturl.at/gtn5M
000
MIMETAS @mimetas.bsky.social · 05/11/2025
New publication from BIOASTER! Using the OrganoPlate® platform and OrganoTEER® device, they built an immunocompetent intestinal model showing that Bifidobacterium infantis and Lacticaseibacillus rhamnosus GG protect the gut barrier from inflammation. www.mdpi.com/2673-8007/5/...
000
MIMETAS @mimetas.bsky.social · 03/11/2025
⏰ Last chance! Join us tomorrow for our webinar on Ready-to-Use Colon Organoids for Multimodal Toxicity Assessment. • Quantify transporter expression & function • Gain morphological insights via Spark® Cyto imaging • Scale workflows for reproducible preclinical evaluation 🔗 lnkd.in/eGXKeYCn
000
MIMETAS @mimetas.bsky.social · 31/10/2025
Something big is coming. A new way to explore and experience MIMETAS' innovation. Stay tuned. 👀
000
MIMETAS @mimetas.bsky.social · 28/10/2025
🗓️ Only 1 week to go! Join our live webinar to learn how physiologically relevant gut organoid models, combined with advanced readout platforms, can elevate the predictive power of preclinical research. Register now: shorturl.at/Qws5a #Organoids #PreclinicalResearch
000